JAC Advance Access originally published online on August 1, 2008
Journal of Antimicrobial Chemotherapy 2008 62(5):895-904; doi:10.1093/jac/dkn311
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Systematic reviews |
Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies
1 Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece 2 Department of Medicine, Caritas St Elizabeth's Medical Center, Tufts University School of Medicine, Boston, MA, USA 3 Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, NY, USA 4 Department of Medicine, Henry Dunant Hospital, Athens, Greece 5 Department of Medicine, Tufts University School of Medicine, Boston, MA, USA
Received 4 April 2008; returned 8 May 2008; revised 2 July 2008; accepted 6 July 2008
* Correspondence address. Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece. Tel: +30-694-611-0000; Fax: +30-210-683-9605; E-mail: m.falagas{at}aibs.gr
Objectives: Antimicrobial drug resistance is spreading among Enterobacteriaceae, limiting the utility of traditionally used agents. We sought to systematically review the microbiological activity and clinical effectiveness of tigecycline for multidrug-resistant (MDR) Enterobacteriaceae, including those resistant to broad-spectrum β-lactams due to the expression of extended-spectrum β-lactamases (ESBLs), AmpC enzymes and carbapenemases (including metallo-β-lactamases).
Methods: PubMed was searched for articles including relevant data.
Results: Twenty-six microbiological and 10 clinical studies were identified. Tigecycline was active against more than 99% of 1936 Escherichia coli isolates characterized by any of the above resistance patterns (including 1636 ESBL-producing isolates) using the US Food and Drug Administration (FDA) breakpoint of susceptibility (MIC 
2 mg/L). Findings were not different using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoint (1 mg/L). Susceptibility rates for Klebsiella spp. with any of the above resistance patterns were 91.2% for 2627 isolates by the FDA criteria and 72.3% for 1504 isolates by the EUCAST criteria (92.3% for 2030 and 72.3% for 1284 ESBL-producing isolates, by the FDA and EUCAST criteria, respectively). The degree of microbiological activity of tigecycline against 576 MDR Enterobacter spp. isolates was moderate. In clinical studies, 69.7% of the 33 reported patients treated with tigecycline achieved resolution of an infection caused by a carbapenem-resistant or ESBL-producing or MDR Enterobacteriaceae.
Conclusions: Tigecycline is microbiologically active against almost all of the ESBL or MDR E. coli isolates and the great majority of ESBL or MDR Klebsiella spp. isolates. Further evaluation of its clinical utility against such resistant Enterobacteriaceae, particularly regarding non-labelled indications, is warranted.
Keywords: glycylcyclines , Citrobacter , Serratia , Proteus , Klebsiella pneumoniae , imipenem
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Daurel, A.-L. Fiant, S. Bremont, P. Courvalin, and R. Leclercq Emergence of an Enterobacter hormaechei Strain with Reduced Susceptibility to Tigecycline under Tigecycline Therapy Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4953 - 4954. [Full Text] [PDF]
|
|
|
|
|
|
P. Shen, Z. Wei, Y. Jiang, X. Du, S. Ji, Y. Yu, and L. Li Novel Genetic Environment of the Carbapenem-Hydrolyzing {beta}-Lactamase KPC-2 among Enterobacteriaceae in China Antimicrob. Agents Chemother., October 1, 2009; 53(10): 4333 - 4338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Nicasio, J. L. Crandon, and D. P. Nicolau In Vivo Pharmacodynamic Profile of Tigecycline against Phenotypically Diverse Escherichia coli and Klebsiella pneumoniae Isolates Antimicrob. Agents Chemother., July 1, 2009; 53(7): 2756 - 2761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lee, G. Patel, S. Huprikar, D. P. Calfee, and S. G. Jenkins Decreased Susceptibility to Polymyxin B during Treatment for Carbapenem-Resistant Klebsiella pneumoniae Infection J. Clin. Microbiol., May 1, 2009; 47(5): 1611 - 1612. [Full Text] [PDF]
|
|